Dr. Blackwell on Margetuximab for HER2+ Breast Cancer

January 19, 2016
Kimberly L. Blackwell, MD

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses the mechanism of action for margetuximab (MGAH22-01) and discusses its potential as a treatment of patients with HER2-positive breast cancer.

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses the mechanism of action for margetuximab (MGAH22-01) and discusses its potential as a treatment of patients with HER2-positive breast cancer.

The constant domain of margetuximab, a HER2-targeting monoclonal antibody engineered for increased Fc-domain binding, has been changed by five amino acids, Blackwell explains. The agent stimulates natural killer cells and tumor-associated macrophages more and inhibits the inhibitory immune cells less. This should offer more of a vigorous immune response against HER2.

Phase I/II data examining the efficacy of margetuximab was presented at the 2015 ASCO Annual Meeting. A phase III study is ongoing, she adds.

x